Blog
Published June 21, 2023
Monica Martin de Bustamante, Sr. Partner of Trinity’s Evidence, Value, Access, and Pricing (EVAP) team, moderated an exciting conversation at ISPOR 2023 Global in Boston earlier this month. Monica spoke with Lisa Marsch, Ph.D., Benjamin Parcher, PharmD, MS, and Fulton Velez, MD, MS, MBA, all experts in the field of Digital Therapeutics (DTx), about the role of evidence development in the approval of DTx to date, and what evidence development requirements could look like in the next five years.
Past…
Read Now
Webinars
Available On Demand
The unprecedented availability of rich RWE data sources gives HEOR, Value and Access and Medical leaders the opportunity to be more intentional than ever before. High-quality, compelling evidence is now a necessity, not just for high-value therapies playing in the rare disease space—but also more broadly, to show reduced unmet needs, health care resource utilization (HCRU) and cost offsets.
Deep experience using industry-leading data sources, tech-enabled methodologies and therapeutic expertise allow Trinity experts to choose the right data for each…
Watch Now
Blog
Published June 16, 2023
Last month, Trinity attended the ISPOR 2023 conference in Boston. The main theme of the conference was “Impacting Innovation, Value and Healthcare Decision Making”, which facilitated unique discussions and workshops across different stakeholders in the life sciences, including manufacturers, regulatory leaders and health economists. Topics included discussions on the role of artificial intelligence (AI) in HEOR, innovation in evidence generation, the latest trends in health policy and a myriad of others.
A highlight for Trinity Life Sciences was presenting 12…
Read Now
Webinars
Available On Demand
Biosimilar versions of adalimumab have launched in the U.S., ending blockbuster therapy Humira’s lengthy market exclusivity and long-running commercial success. In parallel, in the creation of the Inflation Reduction Act (IRA), the U.S. joins Europe and other major markets in constraining the opportunity for medicines during their market exclusivity window. The life sciences industry now seeks to understand how the vision for commercial success will evolve while in parallel navigating new artificial intelligence (AI) and other general-purpose technologies (GPTs) technologies…
Watch Now
Blog
Published April 21, 2023
Executive Summary
Biosimilar versions of adalimumab have launched in the U.S., ending blockbuster therapy Humira’s lengthy market exclusivity and long-running commercial success.
In parallel, in the creation of the Inflation Reduction Act (IRA), the U.S. joins Europe and other major markets in constraining the opportunity for medicines during their market exclusivity window.
Trinity’s Take
These events usher in a new era for the life sciences industry, necessitating new thinking around development and commercialization strategy.
Historic reliance on the U.S. market…
Read Now
Webinars
Available On Demand
Join Trinity Life Sciences’ Evidence, Value, Access and Pricing and Cell & Gene Therapy experts for a deeper look at the market access trends that will present the most impactful opportunities and challenges for life sciences organizations in 2023.This webinar will expand upon the trends discussed in the recently released white paper entitled “Global Market Access Trends: 2022 Edition,” focusing on evolving evidence expectations, increasing price transparency regulation and cell & gene therapy expansion.
Key Webinar Topics
How can life…
Watch Now
Webinars
Available On Demand
Is your company planning to begin commercial contracting or preparing to contract within a new channel?
If you are a leader in a pre-commercial or commercial emerging life sciences company facing these challenges, this webinar is designed for you.
Join our experts from TGaS Advisors, a division of Trinity Life Sciences, as we share what you need to know whether you are embarking on your commercial contracting journey or thinking about a new contracting channel such as payer contracting, provider…
Watch Now
White Papers
Trinity Life Sciences’ Evidence, Value, Access and Pricing experts identify the key global market access trends that will enable life sciences executives to identify opportunities, combat challenges and ultimately secure success in 2023.
Download this white paper to understand:
The five key market access trends emanating from 2022 that foretell the opportunities and challenges that lie ahead in 2023 (and beyond).
In-depth insights from 11 U.S. and 24 ex-U.S. payers from Trinity Life Sciences’ ‘Global Market Access Payer Survey’.
How…
Read Now
Webinars
Available On Demand
Trinity invites life sciences executives to join us for a dynamic discussion on the most common high-impact challenges inherent in Business Development:
What contributes to inaccurate pricing and market access assumptions in the quick-paced Business Development process?
How do you de-risk pricing and access at each stage of the diligence process?
Chad Faulkner, Partner in Trinity’s Strategic Advisory practice, will host this session and moderate a panel with special guests Monica Martin De Bustamante—Senior Partner & Head of Evidence, Value,…
Watch Now
Webinars
Available On Demand
What do ‘pricing inflation penalties’ actually mean for manufacturers of biopharma products?
Explore the impact of the Inflation Reduction Act (IRA) on biopharmaceutical product net prices and contract strategies as manufacturers adapt to new U.S. market conditions.
In this webinar, Trinity Life Sciences’ Evidence, Value, Access & Pricing practice experts will provide a high-level review of IRA policy updates before exploring the implications for currently marketed Medicare Part B and Part D therapies, as well as for future product launches.…
Watch Now
